Ten Years of Rizatriptan: From Development to Clinical Science and Future Directions

Authors

  • Richard J. Hargreaves PhD,

    1. From the Merck Research Laboratories, West Point, PA (R. Hargreaves, C. Lines, and T. Ho); The David Geffen School of Medicine at UCLA, Los Angeles, CA (A. Rapoport); The New England Center for Headache, Stamford, CT, USA (F. Sheftell).
    Search for more papers by this author
  • Chris R. Lines PhD,

    1. From the Merck Research Laboratories, West Point, PA (R. Hargreaves, C. Lines, and T. Ho); The David Geffen School of Medicine at UCLA, Los Angeles, CA (A. Rapoport); The New England Center for Headache, Stamford, CT, USA (F. Sheftell).
    Search for more papers by this author
  • Alan M. Rapoport MD,

    1. From the Merck Research Laboratories, West Point, PA (R. Hargreaves, C. Lines, and T. Ho); The David Geffen School of Medicine at UCLA, Los Angeles, CA (A. Rapoport); The New England Center for Headache, Stamford, CT, USA (F. Sheftell).
    Search for more papers by this author
  • Tony W. Ho MD,

    1. From the Merck Research Laboratories, West Point, PA (R. Hargreaves, C. Lines, and T. Ho); The David Geffen School of Medicine at UCLA, Los Angeles, CA (A. Rapoport); The New England Center for Headache, Stamford, CT, USA (F. Sheftell).
    Search for more papers by this author
  • Fred D. Sheftell MD

    1. From the Merck Research Laboratories, West Point, PA (R. Hargreaves, C. Lines, and T. Ho); The David Geffen School of Medicine at UCLA, Los Angeles, CA (A. Rapoport); The New England Center for Headache, Stamford, CT, USA (F. Sheftell).
    Search for more papers by this author

  • Conflict of Interest: Many of the studies reviewed in this article were funded by Merck Research Laboratories. Drs. Hargreaves, Lines, and Ho are employees of Merck and own stock or stock options in Merck. Drs. Rapoport and Sheftell have received research funding from Merck and have acted as paid consultants for Merck.

R. Hargreaves, Merck Research Laboratories, West Point, PA 19486, USA.

Abstract

The year 2008 marked the 10th anniversary since rizatriptan was first launched for the acute treatment of migraine. In this article we discuss the concepts that motivated the preclinical and clinical development of rizatriptan, the clinical evidence that has driven its use over the past decade, rizatriptan's overall contribution to the field, and future directions for research.

Ancillary